Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 5, 2012, Pages 498-503

  Wells, James Leroy ^a   Shirai, Keisuke ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

cetuximab; chemotherapy; immunosuppression; mammalian target of rapamycin inhibitor; organ transplant recipient; radiation; squamous cell carcinoma of the skin; transplant

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

BASAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; GRAFT RECIPIENT; HUMAN; ORGAN TRANSPLANTATION; REVIEW; SKIN CARCINOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE;

CARCINOMA, SQUAMOUS CELL; HUMANS; ORGAN TRANSPLANTATION; SKIN NEOPLASMS;

EID: 84866736011     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318201a3ef     Document Type: Review

References (47)

1. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007;143:889-892.
2. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999;85:1758-1764.
3. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation. 2004;77:574-579.
4. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant. 2008;8:2192-2198.
5. Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol. 2006;142:755-758.
6. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl. 2000;6:253-262.
7. Perera GK, Child FJ, Heaton N, et al. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol. 2006;154:868-872.
8. Terhorst D, Drecoll U, Stockfleth E, et al. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol. 2009;161(suppl 3):85-89.
9. Ulrich C, Jurgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(suppl 3):78-84.
10. Kuijken I, Bouwes Bavinck JN. Skin cancer risk associated with immunosuppressive therapy in organ transplant recipients: epidemiology and proposed mechanisms. BioDrugs. 2000;14: 319-329.
11. Ulrich C, Schmook T, Sachse MM, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg. 2004;30(4 Pt 2):622-627.
12. Stockfleth E, Ulrich C, Meyer T, et al. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251-258.
13. Moloney FJ, Kelly PO, Kay EW, et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg. 2004;30(4 Pt 2): 674-678.
14. Veness MJ, Harris D. Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas Radiol. 2007. 2007;1:9.
15. Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):642-650.
16. Herman S, Rogers HD, Ratner D. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Skin Med. 2007;6:234-238.
17. Stockfleth E, Nindl I, Sterry W, et al. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg. 2004;30: 604-609.
18. Schmook T, Nindl I, Ulrich C, et al. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol. 2003; 149(suppl 66):20-24.
19. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Skin cancers in organ transplant recipients. Ann Transplant. 1997;2:28-32.
20. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003;139: 301-306.
21. Buell JF, Hanaway MJ, Thomas M, et al. Skin cancer following transplantation: the israel penn international transplant tumor registry experience. Transplant Proc. 2005;37:962-963.
22. Hoyo E, Kanitakis J, Euvrard S, et al. Proliferation characteristics of cutaneous squamous cell carcinomas developing in organ graft recipients. Comparison with squamous cell carcinomas of nonimmu-nocompromised hosts by counting argyrophilic proteins associated with nucleolar organizer regions. Arch Dermatol. 1993;129:324-327.
23. Carucci JA, Martinez JC, Zeitouni NC, et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004;30(4 Pt 2):651-655.
24. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1-17. quiz 8-20.
25. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976-990.
26. Christenson LJ, Geusau A, Ferrandiz C, et al. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):598-603.
27. Fujisawa Y, Umebayashi Y, Ichikawa E, et al. Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: a report of two cases. J Am Acad Dermatol. 2006;55(5 suppl):S81-S85.
28. Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66:1692-1696.
29. Guthrie TH Jr, McElveen LJ, Porubsky ES, et al. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985;55:1629-1632.
30. Merimsky O, Neudorfer M, Spitzer E, et al. Salvage cisplatin and adriamycin for advanced or recurrent basal or squamous cell carcinoma of the face. Anticancer Drugs. 1992;3:481-484.
31. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22:32-34.
32. Goldberg H, Tsalik M, Bernstein Z, et al. Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas. Harefuah. 1994;127:217-221, 86.
33. Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342-346.
34. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67:2030-2032.
35. Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002;20:364-370.
36. Brewster AM, Lee JJ, Clayman GL, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007;25: 1974-1978.
37. Martinez JC, Otley CC, Okuno SH, et al. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg. 2004;30(4 Pt 2):679-686.
38. Iaria G, Anselmo A, De Luca L, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports. Transplant Proc. 2007;39:2036-2037.
39. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883-889.
40. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004;18:446-449.
41. Chiurchiu C, Carreno CA, Schiavelli R, et al. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc. 2010;42:277-279.
42. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-589.
43. Fernandez A, Marcen R, Pascual J, et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc. 2006;38:2453-2455.
44. Jalili A, Pinc A, Pieczkowski F, et al. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges. 2008;6:1066-1069.
45. Suen JK, Bressler L, Shord SS, et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007;18:827-829.
46. Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin: Preliminary results of a phase II multicenter study. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). [Abstract]. 2008 May 20, 2008;26(No 15S):9042.
47. Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study. J Clin Oncol. 2010;28:2010. (suppl; abstr 8510).